Key result
Combined statin and metformin lowers CRP and lipids versus metformin alone in PCOS.
Why the study?
Does the combination of statins and metformin improve lipid, inflammation, and insulin parameters in women with polycystic ovary syndrome?
Population
Women with polycystic ovary syndrome
Comparison
Statins combined with metformin, or statin… vs Metformin alone, or placebo
Design
Meta-analysis
Authors
Loading...
Supports statin addition to metformin for CRP and lipid reduction in PCOS; extends meta-analytic evidence on inflammation but leaves insulin effects open.
Meta-Analysis
Does the combination of statins and metformin improve lipid, inflammation, and insulin parameters in women with polycystic ovary syndrome?
Standardized Mean Difference: -0.91 (95% CI -1.81–-0.02)
p-value: p=0.046
Combined statin and metformin therapy improves lipid and inflammation parameters but does not effectively improve insulin sensitivity or reduce hyperandrogenism in women with PCOS.
Sun et al. (2015) conducted a meta-analysis in Polycystic ovary syndrome (PCOS). Statins with metformin vs. Metformin alone was evaluated on C reactive protein levels (SMD -0.91, 95% CI -1.81 to -0.02, p=0.046). In women with PCOS, combined statin and metformin therapy significantly decreased C-reactive protein (SMD -0.91; 95% CI -1.81 to -0.02; p=0.046) and lipid levels compared to metformin alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: